Supporting Information for

# A MXene-Based Bionic Cascaded-Enzyme Nanoreactor for Tumor

# Phototherapy/Enzyme Dynamic Therapy and Hypoxia Activated

# Chemotherapy

Xiaoge Zhang<sup>1</sup>, Lili Cheng<sup>1</sup>, Yao Lu<sup>1</sup>, Junjie Tang<sup>1</sup>, Qijun Lv<sup>2</sup>, Xiaomei Chen<sup>1</sup>, You Chen<sup>1</sup>, Jie Liu<sup>1, \*</sup>

<sup>1</sup> School of Biomedical Engineering, Shenzhen Campus of Sun Yat-sen University, No. 66, Gongchang Road, Guangming District, Shenzhen, Guangdong 518107, P. R. China

<sup>2</sup>Department of General Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510006, P. R. China

\*Corresponding author. E-mail: <u>liujie56@mail.sysu.edu.cn</u> (Jie Liu)

# S1 Western Blot Analysis of CD47 Expression



Fig. S1 Western blot analysis of CD47 expression on surface of gene-transfected 4T1 cells ( $4T1^{CD47}$ ) and wild-type 4T1 cells

# S2 Characterization of the Exfoliated Ti<sub>3</sub>C<sub>2</sub> Nanosheets



**Fig. S2 a** SEM image of exfoliated  $Ti_3C_2$  nanosheets. **b** FITR spectra characterization of the exfoliated  $Ti_3C_2$  nanosheets. **c** Raman spectra characterization of the exfoliated  $Ti_3C_2$  nanosheets

## **S3 Enzyme Loading Efficiency of TGC**



Fig. S3 Protein loading efficiency of TG, TC and TGC

**S4 UV Characterization and Drug Loading and Encapsulation Efficiency Detection** 



**Fig. S4 a** UV spectra characterization of different samples. **b** The drug loading and entrapment efficiency of TGC/TPZ with different ratio.

**S5** Characterization of the meTGCT Nanoreactor



Fig. S5 a TEM image of meTGCT. b SEM image of meTGCT

#### S6 SDS-PAGE Protein Analysis of meTGCT



Fig. S6 SDS-PAGE protein analysis of  $m_eTGCT$ . a) maker, b)  $4T1^{CD47}$  cell membrane, c) GOX, d) CPO, e)  $m_eTG$ , f)  $m_eTG$ , g)  $m_eTGC$ , h)  $m_eTGCT$ 



S7 Stability of meTGCT

**Fig. S7 a** The size stability of m<sub>e</sub>TGCT in PBS during one week. **b** The photographs of TGCT and m<sub>e</sub>TGCT on day 0 and day 7

### S8 Photothermal Effects of meTGCT in vitro



**Fig. S8 a** Temperature change of  $m_eTGCT$  with different concentrations under 808 nm laser (1.5 W cm<sup>-2</sup>) irradiation for 10 min. **b** Four cycles of temperature variation of  $m_eTGCT$  buffer solution (50 µg mL<sup>-1</sup>) with continuous 808 nm laser irradiation (1.5 W cm<sup>-2</sup>, 10 min) and natural cooling. **c** The photothermal conversion efficiency of the  $m_eTGCT$  solution under 808 nm laser. Inset is plot of linear time data versus  $-ln\theta$ , which was from the cooling stage

**S9** Influence of Different Concentrations of GOX on pH Values of PBS



**Fig. S9** Time-dependent changes in pH values of PBS containing GOX with different concentrations in the presence of 4 mg mL<sup>-1</sup> glucose



**S10 Detection of the HClO Content** 

**Fig. S10 a** HClO production content of PBS containing  $m_eTGCT$  and different concentrations of  $H_2O_2$  in the presence of 4 mg mL<sup>-1</sup> glucose and 25 mM Cl<sup>-</sup>. **b** HClO production content of PBS containing  $m_eTGCT$  and different concentrations of glucose in the presence of 25 mM Cl<sup>-</sup>. **c** HClO production content of PBS containing  $m_eTGCT$  and different concentrations methods of Cl<sup>-</sup> in the presence of 4 mg mL<sup>-1</sup> glucose

#### S11 Detection of the Relative Enzymatic Activity



**Fig. S11 a** The relative GOX enzymatic activity of various samples with or without 808 nm (1.5 W cm<sup>-2</sup>, 3 min) and 635 nm (0.5 W cm<sup>-2</sup>, 5 min) lasers irradiation. **b** The relative CPO enzymatic activity of various samples with or without 808 nm (1.5 W cm<sup>-2</sup>, 3 min) and 635 nm (0.5 W cm<sup>-2</sup>, 5 min) lasers irradiation

## S12 Detection of the <sup>1</sup>O<sub>2</sub> Quantum Yields



Fig. S12 The time dependent  $\triangle OD$  of the  ${}^{1}O_{2}$  indicator DPBF incubated with Ti<sub>3</sub>C<sub>2</sub>, m<sub>e</sub>T, m<sub>e</sub>TGCT and MB with or without 635 nm laser (0.5 W cm<sup>-2</sup>) for 5 min in O<sub>2</sub>-saturated PBS solution

### S13 TPZ Release Performances from meTGCT



Fig. S13 TPZ release performances from  $m_eTGCT$  under different conditions

S14 4T1 Cells Internalization of meTGC by Flow Cytometry



Fig. S14 Flow cytometric results of the uptake amount of C6, TGC/C6, and  $m_e$ TGC/C6 by 4T1 cells

### S15 Macrophages Internalization of meTGC by Flow Cytometry



Fig. S15 Flow cytometric results of the uptake amount of C6, TGC/C6 and  $m_e$ TGC/C6 by macrophages

## S16 Intracellular ROS Detection by Flow Cytometry



**Fig. S16 a** Quantitative internalization ROS detection of 4T1 cells with different treatments for 4 h with/without 635 nm laser (0.5 W cm<sup>-2</sup>, 5 min) by flow cytometry. **b** Intracellular ROS detection in 4T1 cells treated with different samples at 4 h by flow cytometry under 635 nm laser irradiation (0.5 W cm<sup>-2</sup>, 5 min) (\*\*\*p < 0.001, \*\*p < 0.01, \*p < 0.05, n = 3)

## S17 Cellular Hypoxia Detection of 4T1 Cells



**Fig. S17** Cellular hypoxia detection of 4T1 cells incubated with different samples in DMEM by flow cytometry using a hypoxia probe under 635 nm laser irradiation (0.5 W/cm<sup>2</sup>) for 5 min. (\*\*\*p < 0.001, \*\*p < 0.01, \*p < 0.05, n = 3)

S18 In vitro Photothermal Effects of TGC and meTGC



Fig. S18 The temperature changes of 4T1 cells in 96-well plates treated with TGC or  $m_e$ TGC for 4 h, before and after 808 nm (1.5 W cm<sup>-2</sup>) laser irradiation for different time.



S19 In vitro Anti-tumor Effects of Ti<sub>3</sub>C<sub>2</sub> and meT

**Fig. S19 a** 4T1 cell viability of treatment with  $Ti_3C_2$  with or without 808 nm (1.5 W cm<sup>-2</sup>, 3 min) and 635 nm (0.5 W cm<sup>-2</sup>, 5 min) laser irradiation. **b** 4T1 cell viability of treatment with m<sub>e</sub>T with or without 808 nm (1.5 W cm<sup>-2</sup>, 3 min) and 635 nm (0.5 W cm<sup>-2</sup>, 5 min) laser irradiation. **c** 4T1 cell viability of treatment with TPZ of different concentrations in normoxic or hypoxia environment. **d** 4T1 cell viability of varying formulations with high glucose (4.5 mg mL<sup>-1</sup>) or low glucose (1 mg mL<sup>-1</sup>) under 808 nm (1.5 W cm<sup>-2</sup>, 3 min) and 635 nm (0.5 W cm<sup>-2</sup>, 5 min) laser irradiation. (\*\*\*p < 0.001, \*\*p < 0.05, n = 5)



#### S20 Photothermal Effect of TGC and meTGC in vivo

Fig. S20 The temperature images of 4T1 cancer-bearing mice exposed to 808 nm laser  $(1.5 \text{ W cm}^{-2})$  within 5 min

S21 Representative Immunofluorescence Staining Images of Tumors Stained with the Hypoxyprobe Kit with Different Treatments



**Fig. S21 a** Representative immunofluorescence images of tumor slices stained with the hypoxyprobe kit after i.v. injection of G1) Control, G2) m<sub>e</sub>T, G3) m<sub>e</sub>TG, G4) TGC, G5) m<sub>e</sub>TGC, G6) TGCT, G7) m<sub>e</sub>TGCT, G8) TGCT+laser, G9) m<sub>e</sub>TGCT+laser. **b** The semiquantitative analysis of **a** 

S22 Survive Curve of the Mice with Different Treatments



Fig. S22 Kaplan-Meier survival analysis of 4T1 tumor-bearing mice after various treatments



S23 Blood Biochemical Analysis of the Mice with Different Treatments

**Fig. S23** Blood biochemical results of the mice with different treatments at 21-day postinjection. The results show the mean and SD of **a** alanine aminotransferase (ALT), **b** aspartate aminotransferase (AST), **c** albumin (ALB), **d** alkaline phosphatase (ALP), **e** gamma glutamyl transferase ( $\gamma$ -GT), **f** total protein (TP), **g** blood urea nitrogen (BUN), **h** creatinine (CR) and **i** glucose (GLU). G1) Control, G2) m<sub>e</sub>T, G3) m<sub>e</sub>TG, G4) TGC, G5) m<sub>e</sub>TGC, G6) TGCT, G7) m<sub>e</sub>TGCT, G8) TGCT+laser, G9) m<sub>e</sub>TGCT+laser

# S24 HE Staining of Major Organs



**Fig. S24** H&E staining of tissues were harvested from the health mice of different groups

S25 H&E Staining Images of Tumors with Different Treatments



**Fig. S25** H&E staining of tumor tissues dissected from the mice in various groups (G1) Control, G2) m<sub>e</sub>T, G3) m<sub>e</sub>TG, G4) TGC, G5) m<sub>e</sub>TGC, G6) TGCT, G7) m<sub>e</sub>TGCT, G8) TGCT+laser, G9) m<sub>e</sub>TGCT+laser)





**Fig. S26 a** Representative immunofluorescence images of proliferating cells (Ki67positive) of the tumors with different treatments. G1) Control, G2) m<sub>e</sub>T, G3) m<sub>e</sub>TG, G4) TGC, G5) m<sub>e</sub>TGC, G6) TGCT, G7) m<sub>e</sub>TGCT, G8) TGCT+laser, G9) m<sub>e</sub>TGCT+laser. **b** The semiquantitative analysis of **a**